RA Capital Management »

Urogen Pharma shares owned by RA Capital Management

Quarter-by-quarter ownership of Urogen Pharma (URGN) shares owned by RA Capital Management from 13F filings

Historical chart of RA Capital Management investment in Urogen Pharma

Tip: Access up to 7 years of quarterly data

All positions including Urogen Pharma held by RA Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Urogen Pharma by RA Capital Management

Quarter filed Position value Share count Share price at filing
2023-12-31 $46M 3.1M 15.00
2023-09-30 $21M 1.5M 14.01

More positions owned by RA Capital Management

Ascendis Pharma A/s - SH (ASND)
Immunogen SH
Vaxcyte SH (PCVX)
Legend Biotech Corp- SH (LEGN)
Rhythm Pharmaceuticals SH (RYTM)
Aerovate Therapeutics SH (AVTE)
Inhibrx SH (INBX)
Cymabay Therapeutics SH
Biogen SH (BIIB)
Rxsight SH (RXST)
89bio SH (ETNB)
Verona Pharma Plc - SH (VRNA)
Day One Biopharmaceuticals I SH (DAWN)
An2 Therapeutics SH (ANTX)
Tyra Biosciences SH (TYRA)

View all positions for RA Capital Management

Top funds holding Urogen Pharma

RA Capital Management
Dr. Jeffrey R. Jay, M.D.
Credit Suisse
Harel Insurance Investments & Financial Services
Migdal Insurance & Financial Holdings
Millennium Management
Opaleye Management
Superstring Capital Management
Laurion Capital Management
Wells Fargo & Company
Citadel Advisors
Vanguard Group
ARK Investment Management
AlphaCentric Advisors
Schonfeld Strategic Advisors

View all funds holding Urogen Pharma